Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Analysis of Solvency Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Solvency Ratios (Summary)

Vertex Pharmaceuticals Inc., solvency ratios

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Debt Ratios
Debt to equity
Debt to equity (including operating lease liability)
Debt to capital
Debt to capital (including operating lease liability)
Debt to assets
Debt to assets (including operating lease liability)
Financial leverage
Coverage Ratios
Interest coverage
Fixed charge coverage

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Leverage Ratios Trends
The debt to equity ratio shows a consistent decline from 0.07 in 2020 to 0.01 in 2024, indicating a decreasing reliance on debt relative to equity over the analyzed period. Similarly, the debt to capital ratio decreases steadily from 0.06 in 2020 to 0.01 in 2024, reflecting an improving capital structure with reduced debt proportion.
When including operating lease liabilities, the debt to equity and debt to capital ratios follow a similar declining trend from 2020 to 2023 but exhibit a notable increase in 2024 to 0.11 and 0.10 respectively. This reversal suggests a rise in lease-related liabilities affecting the overall leverage at the end of the period.
The debt to assets ratio declines from 0.05 in 2020 to 0.01 in 2024, indicating decreasing debt levels relative to total assets. However, the inclusion of operating lease liabilities in the debt to assets measure also shows an increase in 2024 to 0.08 after a prior downward trend, echoing the impact of lease liabilities noted above.
Financial Leverage
Financial leverage experiences a gradual decrease from 1.35 in 2020 to 1.29 in 2023, suggesting a reduction in the use of borrowed funds to finance assets. However, it rises to 1.37 in 2024, which corresponds with the increase in debt ratios including operating lease liabilities, indicating growing leverage pressures in the most recent year.
Interest Coverage Ratios
The interest coverage ratio shows volatility: starting at 54.6 in 2020, decreasing to 45.4 in 2021, then substantially increasing to 78.23 in 2022 and further to 100.32 in 2023, before sharply falling to 9.12 in 2024. This pattern suggests initially strong ability to cover interest expenses, a significant improvement through 2023, followed by a marked decline in 2024, raising concerns about interest expense coverage in the latest period.
Fixed charge coverage ratio echoes the interest coverage trend, with values declining from 39.35 in 2020 to 29.62 in 2021, then improving to 47.97 in 2022 and slightly further to 48.66 in 2023, before plummeting to 2.85 in 2024. This significant drop in 2024 indicates potential difficulty in covering fixed charges beyond just interest, highlighting possible liquidity or expense management challenges.

Debt Ratios


Coverage Ratios


Debt to Equity

Vertex Pharmaceuticals Inc., debt to equity calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Current finance lease liabilities
Long-term finance lease liabilities
Total debt
 
Shareholders’ equity
Solvency Ratio
Debt to equity1
Benchmarks
Debt to Equity, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Debt to Equity, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Debt to Equity, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total debt
The total debt demonstrates a consistent downward trend throughout the period analyzed. Beginning at 581,476 thousand US dollars in 2020, it declines steadily each year to reach 118,000 thousand US dollars by 2024. This represents a significant reduction, suggesting a strategic effort to deleverage the company's financial position over the five-year span.
Shareholders’ equity
Shareholders' equity exhibits a strong upward trajectory, increasing substantially from 8,686,815 thousand US dollars in 2020 to a peak of 17,580,400 thousand US dollars in 2023. There is a slight decrease in 2024 to 16,409,600 thousand US dollars, but overall, the equity base nearly doubles over the period. This growth in equity indicates improved net asset strength and potentially increased retained earnings or capital contributions.
Debt to equity ratio
The debt to equity ratio decreases markedly from 0.07 in 2020 to 0.01 by 2024. This decline reflects the combined effect of decreasing total debt and increasing shareholders’ equity, highlighting a strengthening capital structure and reduced financial risk. The ratio’s steady reduction implies enhanced financial stability and potentially greater investor confidence in the company’s balance sheet management.

Debt to Equity (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Current finance lease liabilities
Long-term finance lease liabilities
Total debt
Current operating lease liabilities
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Shareholders’ equity
Solvency Ratio
Debt to equity (including operating lease liability)1
Benchmarks
Debt to Equity (including Operating Lease Liability), Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Debt to Equity (including Operating Lease Liability), Sector
Pharmaceuticals, Biotechnology & Life Sciences
Debt to Equity (including Operating Lease Liability), Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total debt (including operating lease liability)
The total debt exhibited a somewhat fluctuating pattern over the observed periods. Initially, debt increased slightly from 942,460 thousand US dollars at the end of 2020 to 967,400 thousand US dollars in 2021. This was followed by a steady decline to 899,700 thousand US dollars in 2022 and further down to 808,400 thousand US dollars in 2023. However, in 2024, there was a significant jump to 1,749,500 thousand US dollars, indicating a notable increase in leverage or financing activities during that year.
Shareholders’ equity
Shareholders' equity showed a consistent upward trajectory from 2020 through 2023, rising from 8,686,815 thousand US dollars in 2020 to 17,580,400 thousand US dollars in 2023. This reflects a strong growth in the company’s net assets or retained earnings over the period. In 2024, a slight decline was observed, with equity decreasing to 16,409,600 thousand US dollars, suggesting either a distribution to shareholders, a reduction in retained earnings, or other equity-related adjustments.
Debt to equity ratio (including operating lease liability)
The debt to equity ratio declined steadily from 0.11 in 2020 to a low of 0.05 in 2023, indicating an improvement in the company's financial leverage and potentially stronger equity backing relative to debt. In 2024, this ratio reversed back to 0.11, consistent with the increase in total debt that year, pointing to a higher financial risk or a strategic change in capital structure.

Debt to Capital

Vertex Pharmaceuticals Inc., debt to capital calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Current finance lease liabilities
Long-term finance lease liabilities
Total debt
Shareholders’ equity
Total capital
Solvency Ratio
Debt to capital1
Benchmarks
Debt to Capital, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Debt to Capital, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Debt to Capital, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =

2 Click competitor name to see calculations.


Total Debt
The total debt exhibits a consistent downward trend over the observed five-year period. Starting at US$581,476 thousand in 2020, total debt decreased yearly, reaching US$118,000 thousand by the end of 2024. This represents a significant reduction in leverage, indicating a strategic effort to reduce borrowing or deleverage the balance sheet substantially.
Total Capital
Total capital shows a steady increase from US$9,268,291 thousand in 2020 to a peak of US$18,007,100 thousand in 2023 before experiencing a decline to US$16,527,600 thousand in 2024. The overall trend over the five years is positive, with capital nearly doubling from 2020 to 2023. The slight decrease in 2024 may suggest a reallocation of capital or other changes in financing structure or equity value.
Debt to Capital Ratio
The debt to capital ratio consistently declined from 0.06 in 2020 to 0.01 in 2024. This decreasing ratio corroborates the reduction in total debt combined with the growth and eventual softening of total capital. The ratio's decline reflects a strengthening capital structure with diminished reliance on debt financing relative to overall capital.
Summary Insights
The observed financial data indicates a clear strategic focus on reducing financial leverage, as evidenced by the substantial decrease in total debt and the debt to capital ratio. The capital base increased significantly during the period examined, enhancing financial stability and possibly supporting growth initiatives. The drop in total capital in the final year, along with the continued decline in debt, may point to a shift in financing strategy or capital deployment decisions that require further analysis. Overall, the company appears to be improving its financial robustness by lowering debt dependency and increasing capital resources.

Debt to Capital (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Current finance lease liabilities
Long-term finance lease liabilities
Total debt
Current operating lease liabilities
Long-term operating lease liabilities
Total debt (including operating lease liability)
Shareholders’ equity
Total capital (including operating lease liability)
Solvency Ratio
Debt to capital (including operating lease liability)1
Benchmarks
Debt to Capital (including Operating Lease Liability), Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Debt to Capital (including Operating Lease Liability), Sector
Pharmaceuticals, Biotechnology & Life Sciences
Debt to Capital (including Operating Lease Liability), Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= ÷ =

2 Click competitor name to see calculations.


Total Debt (Including Operating Lease Liability)
Over the five-year period, the total debt exhibits a generally fluctuating pattern. Starting at approximately $942 million in 2020, debt increased slightly in 2021 to around $967 million, followed by a downward trend through 2023, reaching a low of about $808 million. The year 2024 marks a notable increase, with total debt more than doubling to approximately $1.75 billion. This sharp rise represents a significant change compared to prior years and may indicate an increased reliance on debt financing or new large-scale obligations.
Total Capital (Including Operating Lease Liability)
Total capital demonstrates a steady and substantial increase from 2020 through 2023, rising from roughly $9.63 billion to about $18.39 billion. This growing capital base suggests ongoing expansion or investment activities. However, in 2024, there is a slight decrease to approximately $18.16 billion, indicating a minor contraction or stabilization of capital after previous years of growth.
Debt to Capital Ratio (Including Operating Lease Liability)
The debt to capital ratio trends downward from 0.10 in 2020 to a low of 0.04 in 2023, reflecting a decreasing proportion of debt relative to total capital over most of the period. This suggests a strengthening capital structure with reduced leverage. However, in 2024 the ratio rises sharply back to 0.10, corresponding with the increase in total debt during the same year. This reversal indicates a shift toward higher leverage, potentially increasing financial risk or reflecting strategic financing decisions.

Debt to Assets

Vertex Pharmaceuticals Inc., debt to assets calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Current finance lease liabilities
Long-term finance lease liabilities
Total debt
 
Total assets
Solvency Ratio
Debt to assets1
Benchmarks
Debt to Assets, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Debt to Assets, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Debt to Assets, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


The financial data presents a clear and consistent downward trend in the company's leverage over the analyzed period. Total debt has been steadily reduced each year, falling from $581,476 thousand at the end of 2020 to $118,000 thousand by the conclusion of 2024. This represents a significant decline in debt levels.

In parallel, total assets have shown strong growth, increasing from $11,751,808 thousand in 2020 to a peak of $22,730,200 thousand in 2023, before a slight decrease to $22,533,200 thousand in 2024. The asset base more than doubled over the five-year span, indicating expansion or accumulation of resources.

Accordingly, the debt to assets ratio has decreased consistently from 0.05 in 2020 to 0.01 in 2024. This declining ratio highlights an improvement in the company's financial leverage and overall solvency position, reflecting prudent debt management relative to asset growth.

Debt Reduction
Total debt reduced by approximately 80% over five years, indicating strategic deleveraging.
Asset Growth
Total assets nearly doubled by 2023, plateauing slightly in the final year.
Leverage Ratio
Debt to assets ratio declined from 0.05 to 0.01, demonstrating strengthening balance sheet robustness.

Debt to Assets (including Operating Lease Liability)

Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Current finance lease liabilities
Long-term finance lease liabilities
Total debt
Current operating lease liabilities
Long-term operating lease liabilities
Total debt (including operating lease liability)
 
Total assets
Solvency Ratio
Debt to assets (including operating lease liability)1
Benchmarks
Debt to Assets (including Operating Lease Liability), Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Debt to Assets (including Operating Lease Liability), Sector
Pharmaceuticals, Biotechnology & Life Sciences
Debt to Assets (including Operating Lease Liability), Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= ÷ =

2 Click competitor name to see calculations.


Total Debt (including operating lease liability)
The total debt exhibited a fluctuating trend over the observed periods. Beginning at approximately $942 million in 2020, the debt slightly increased to about $967 million in 2021. Subsequently, it decreased consistently to around $899.7 million in 2022 and further down to $808.4 million in 2023. However, in 2024, there was a significant increase to approximately $1.75 billion, more than doubling from the previous year.
Total Assets
Total assets showed a strong upward trajectory from 2020 through 2023. Starting at roughly $11.75 billion in 2020, assets increased steadily each year, reaching approximately $22.73 billion by the end of 2023. In 2024, the total assets slightly declined to about $22.53 billion but remained near the peak levels achieved in the prior year.
Debt to Assets Ratio (including operating lease liability)
The debt to assets ratio demonstrated a decreasing trend from 2020 through 2023, moving from 0.08 in 2020 down to a low of 0.04 in 2023. This indicates an improving leverage position relative to asset size over this period. However, in 2024, the ratio increased again to 0.08, signaling a return to the leverage level observed in 2020, likely influenced by the substantial rise in total debt during the same year.
Overall Analysis
The financial data reveal a general pattern of asset growth combined with a reduction in leverage from 2020 to 2023, suggesting a strengthening financial position and possibly prudent debt management during these years. The marked increase in total debt in 2024 alongside a marginal decline in total assets resulted in a higher debt to assets ratio, indicating a shift towards higher leverage and potentially increased financial risk in the most recent year.

Financial Leverage

Vertex Pharmaceuticals Inc., financial leverage calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Total assets
Shareholders’ equity
Solvency Ratio
Financial leverage1
Benchmarks
Financial Leverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Financial Leverage, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Financial Leverage, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= ÷ =

2 Click competitor name to see calculations.


Total assets
The total assets exhibited consistent growth over the analyzed period from 2020 to 2023, increasing from approximately 11.75 billion US dollars to 22.73 billion US dollars. However, there was a slight decrease observed in 2024, with total assets declining to around 22.53 billion US dollars. This indicates a strong expansion phase followed by a minor contraction or asset reallocation in the final year.
Shareholders’ equity
Shareholders’ equity also showed a robust upward trend from 8.69 billion US dollars in 2020 to a peak of 17.58 billion US dollars in 2023. In 2024, equity decreased to 16.41 billion US dollars, mirroring the downward adjustment seen in total assets. Despite this reduction, the equity level at the end of 2024 remained significantly higher than at the start of the period, reflecting overall growth in the company's net worth.
Financial leverage
The financial leverage ratio gradually declined from 1.35 in 2020 to a low of 1.29 in 2023, indicating a reduction in the amount of debt used relative to equity during these years. In 2024, the ratio increased to 1.37, surpassing the initial level seen in 2020. This uptick suggests a moderate rise in leverage, which could imply increased borrowing or a relative decrease in equity.

Interest Coverage

Vertex Pharmaceuticals Inc., interest coverage calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Net income (loss)
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Solvency Ratio
Interest coverage1
Benchmarks
Interest Coverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Interest Coverage, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Interest Coverage, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Interest coverage = EBIT ÷ Interest expense
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals notable fluctuations over the five-year period under review, particularly in earnings before interest and tax (EBIT), interest expense, and interest coverage ratio.

Earnings Before Interest and Tax (EBIT)
The EBIT values exhibit a mixed trend. After an initial decrease from approximately 3,174,949 thousand US dollars in 2020 to 2,791,900 thousand US dollars in 2021, there is a marked increase in 2022 and 2023, reaching 4,287,200 and 4,423,900 thousand US dollars respectively. However, a sharp decline is observed in 2024, with EBIT dramatically falling to 279,100 thousand US dollars. This indicates strong profitability in the middle years followed by a significant downturn towards the end of the period.
Interest Expense
Interest expense shows a declining trend over the years. Initially, the expense is 58,151 thousand US dollars in 2020, increasing slightly to 61,500 thousand US dollars in 2021, then steadily decreasing in subsequent years to 54,800 in 2022, 44,100 in 2023, and finally 30,600 thousand US dollars in 2024. This pattern suggests an improvement in debt management or a reduction in interest-bearing liabilities over time.
Interest Coverage Ratio
The interest coverage ratio demonstrates significant variability. Starting from a healthy 54.6 in 2020, it declines to 45.4 in 2021. It then rises sharply to peak at 78.23 in 2022 and further to 100.32 in 2023, reflecting enhanced ability to meet interest obligations during this period. However, the ratio plummets to 9.12 in 2024, corresponding with the steep drop in EBIT. Despite this decrease, it remains above a critical threshold, indicating the company still covers its interest expenses though with reduced margin.

In summary, the company experienced solid EBIT growth and improved interest coverage through 2023, complemented by decreasing interest expenses, suggesting effective financial management. However, the drastic downturn in EBIT and subsequent reduction in interest coverage in 2024 raises concerns about earnings sustainability and potential financial stress in the latest period.


Fixed Charge Coverage

Vertex Pharmaceuticals Inc., fixed charge coverage calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Net income (loss)
Add: Income tax expense
Add: Interest expense
Earnings before interest and tax (EBIT)
Add: Operating lease cost
Earnings before fixed charges and tax
 
Interest expense
Operating lease cost
Fixed charges
Solvency Ratio
Fixed charge coverage1
Benchmarks
Fixed Charge Coverage, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Fixed Charge Coverage, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Fixed Charge Coverage, Industry
Health Care

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 2024 Calculation
Fixed charge coverage = Earnings before fixed charges and tax ÷ Fixed charges
= ÷ =

2 Click competitor name to see calculations.


The financial data reveals several important trends regarding earnings and fixed charges over the observed five-year period.

Earnings before fixed charges and tax
There was an initial decline from 3,198,077 thousand US dollars in 2020 to 2,825,800 thousand in 2021. This was followed by a notable increase, peaking at 4,471,700 thousand in 2023. However, in 2024, there is a sharp and significant drop to 383,000 thousand, far below any previous levels in the period.
Fixed charges
The fixed charges showed a gradual increase over the first four years, rising from 81,279 thousand US dollars in 2020 to 91,900 thousand in 2023. In 2024, fixed charges rose noticeably to 134,500 thousand, marking the highest value in the time frame.
Fixed charge coverage ratio
The coverage ratio, which indicates the ability to meet fixed charges from earnings, decreased from a high 39.35 in 2020 to 29.62 in 2021, reflecting weaker earnings relative to fixed charges. It then improved markedly in 2022 and 2023, reaching its peak at 48.66. In 2024, the ratio plunged sharply to 2.85, reflecting a substantially weakened capacity to cover fixed charges with earnings due to the combined effect of earnings collapsing and fixed charges rising.

Overall, the data suggests a relatively stable to improving operational performance from 2020 through 2023, with strong earnings growth and adequate fixed charge coverage. However, the sudden and dramatic decline in earnings in 2024, alongside increased fixed charges, signals potential financial distress or an extraordinary event adversely impacting profitability and financial stability in that year. The fixed charge coverage ratio's steep drop highlights a significantly reduced margin of safety for meeting financial obligations related to fixed costs in 2024.